Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis
An erratum to this article was published (RMD Open, Jun 2023 ↗)
Main finding · New-onset uveitis rate, MTX vs no MTX (adjusted)Result — go to the resultHazard ratio 0.35 95% CI 0.17–0.75Authors' conclusion
This study demonstrates an independent protective effect of MTX on new-onset uveitis in patients with biological-naïve JIA.
Study context
- Population
- Patients with biological-naïve Juvenile Idiopathic Arthritis (JIA), University Medical Centre Utrecht, the Netherlands
- Participants
- 92 patients
- Comparison
- Methotrexate (MTX) exposure in JIA-U cases vs JIA controls without JIA-U
- JIA-Un = 46
- Controlsn = 46reference
- Outcome
- New-onset uveitis (JIA-U onset) by MTX exposure
Methodological detailsmatched 1:1 on JIA diagnosis date, age at JIA diagnosis, JIA subtype, ANA status and disease duration, multivariable time-varying Cox regression, single-centre
- Matched 1:1 on JIA diagnosis date, age at JIA diagnosis, JIA subtype, ANA status and disease duration
- Multivariable time-varying Cox regression
- Single-centre
Main finding
New-onset uveitis rate, MTX vs no MTX (adjusted)
Hazard ratio
0.35
95% CI 0.17–0.75
MTXvs No MTX
HR 0.35 (95% CI 0.17–0.75)
As reported in the abstract
Observational data: associations, not effects.
Further findings
- MTX discontinuation — Of JIA-U cases who discontinued, developed uveitis within 1 year · JIA-U cases significantly more often discontinued MTX
- 50% · P = 0.03
MTX ever-use and exposure years
- Both ever-use of MTX and exposure years were lower in JIA-U cases than in controls
MTX dose, low (<10 mg/m²/week) vs standard (≥10 mg/m²/week)
- No different effect observed between low and standard MTX dose
Original publication
Methotrexate therapy associated with a reduced rate of new-onset uveitis in patients with biological-naïve juvenile idiopathic arthritis. RMD Open. Published 24 April 2023. doi:10. 1136/ rmdopen-2023-003010
Composed by AI from the published abstract and checked against it. How Briefs are made →